News and Trends 20 Aug 2019 Nabriva Therapeutics Gets FDA Green Light for Pneumonia Antibiotic The US FDA has approved Nabriva Therapeutics’ Xenleta for treating community-acquired bacterial pneumonia, the first in a new class of antibiotics developed to treat this condition. Xenleta, also known as lefamulin, was discovered almost 10 years ago by Nabriva Therapeutics, a spinout company from Novartis split between Austria, Ireland and the US. The approval is […] August 20, 2019 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2018 Another Pneumonia Antibiotic is Close to Treating Patients Nabriva Therapeutics has obtained positive Phase III results for its antibiotic lefamulin and plans to seek FDA approval for the drug by the end of this year. Nabriva Therapeutics has obtained a second round of positive Phase III results for lefamulin, its antibiotic targeting community-acquired pneumonia. The drug was shown to be as effective as […] May 23, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2017 World Antibiotic Awareness Week: Here are Biotech’s Top 5 Strategies to Overcome Resistance This week marks the WHO’s World Antibiotic Awareness Week. We had a look at some of the best work being done by biotechs to fight resistance. An estimated 154 million prescriptions for antibiotics are written each year, but up to 30% are unnecessary. The World Health Organization has set up World Antibiotic Awareness Week to tackle this. This year’s theme is […] November 13, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 18 Sep 2017 Austrian Biotech Scores a Phase III Win in the Fight Against Antibiotic Resistance The novel antibiotic lefamulin brought home late-stage success to Nabriva by proving itself to be on par with the standard treatment in pneumonia. Novartis spinout Nabriva has been developing antibiotics since 2006 and now boasts over 150 employees and a $285M (€239M) market cap. The company just reported that its latest stage program, centered on lefamulin for […] September 18, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 18 Sep 2017 David Chiswell: “We are getting close to the best way of making antibodies” We interviewed David Chiswell, a pioneer in the development of therapeutic antibodies and now the CEO of Kymab, which he has the ambition to turn into the “European Genentech.” David Chiswell was, along with Greg Winter, one of the co-founders of Cambridge Antibody Technology. “We both wanted to start an antibody company,” says Chiswell. “And […] September 18, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Infographics 21 Feb 2017 Infographic: The Biggest Biotech Company in Each European Country We had a look into European biotech and created a map with the biggest biotech companies in each country, according to their market cap. Biotech is one of the biggest employers in Europe, where companies of all sizes strive to bring the most innovative technology to the market. To illustrate the dynamic biotech ecosystem in […] February 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email